#USA #San Diego #Class Action #Securities Fraud #Regeneron Pharmaceuticals

Introduction

In recent news, the law firm Robbins Geller Rudman & Dowd LLP has announced the opportunity for investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to lead a class action lawsuit. The lawsuit is aimed at shareholders who purchased or acquired Regeneron stock between August 1, 2025, and May 15, 2026. If you have suffered substantial losses during this period, you may be eligible to seek appointment as a lead plaintiff in this class action.

What’s at Stake?

The class action lawsuit against Regeneron, registered as Cheatham v. Regeneron Pharmaceuticals, Inc., alleges that the pharmaceutical giant, along with some of its top executives, has violated the Securities Exchange Act of 1934. The allegations mainly focus on misleading statements made by the company concerning the Phase III Fianlimab-Libtayo Study, which is pivotal for assessing the company's portfolio of treatments for serious disorders.

Allegations Against Regeneron

According to the allegations, Regeneron is said to have created a false narrative surrounding the success of the Phase III study. Specifically, it is claimed that:
1. Defendants misrepresented data, creating a misleading impression of the trial's reliability and potential success.
2. They reportedly downplayed significant risks to the trials’ validity, including a slowdown in event rates which could impact the outcomes.
3. The preliminary statistical assumptions used were flawed, which could have detrimental implications for the overall study results.
4. There was a purported failure of the active treatment arm to show significant clinical advantage over standard therapies.

On April 29, 2026, during an earnings call, it was disclosed that the Phase III study had seen changes that increased the number of patients eligible for progression-free survival analysis. This revelation reportedly caused the Regeneron stock to fall by over 6%. Following this, a press release on May 15, 2026, revealed that the study did not reach statistical significance for its primary endpoint, leading to a near 10% decline in stock price.

The Role of Lead Plaintiffs

The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Regeneron shares during the specified period to petition for the role of lead plaintiff in this class action. The lead plaintiff is typically an investor with the most significant financial stake in the outcome of the case and acts on behalf of other investors in guiding the lawsuit proceedings.

What to Do if You Qualify

If you're an investor who believes you qualify to lead this class action, your next steps should include confirming your eligibility based on your stock purchases during the defined class period. Interested investors can gather additional information and provide their details through a dedicated online form or by contacting the law firm directly at 800/851-7783 or via email.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is a prominent law firm distinguished for its role in securities fraud and shareholder rights litigation. The firm has consistently excelled in class-action recoveries over the years, ranking number one in investor recoveries in the last five years. With a robust legal team and a commitment to protecting investor rights, Robbins Geller is one of the largest plaintiffs' firms, obtaining some of the most significant securities class action recoveries in U.S. history.

Conclusion

The ongoing issues surrounding Regeneron Pharmaceuticals provide an important opportunity for affected investors to take action. If you have endured financial losses due to alleged misstatements and misleading information from Regeneron, consider joining the class action. The deadline for applying as a lead plaintiff is approaching quickly, and timely action will be crucial for those looking to stake a claim in this significant legal battle.